previously several years, the UK has witnessed a revolution in healthcare excess weight‑decline treatment plans — from the introduction of semaglutide (Wegovy®) into the growing attractiveness of tirzepatide (Mounjaro®). Now, One more name is drawing consideration in each clinical and general pub